HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Evolving' With Health Care, CHPA Considers Device, Supplement Sectors

This article was originally published in The Pink Sheet

Executive Summary

CHPA's 2020 project is an internal analysis on how it can evolve as its members broaden into additional business categories. President and CEO Scott Melville says the effort is necessary to keep up with the “lightning speed” of health care changes.

You may also be interested in...



OTC Monograph Reform, User Fee Legislation Coming 'Any Day' – CHPA

Imminent OTC monograph reform legislation signals an agreement between industry and FDA on details of a proposal, which also includes a potential user fee program. CHPA also is hopeful for legislation restoring direct OTC drug purchases with pre-tax savings accounts.

Hawaii's Proposed Oxybenzone Sunscreen Ban Fails Science Test – CHPA

CHPA commits to fighting against onslaught of bills in Hawaii aiming to ban or limit the use of oxybenzone-containing sunscreens, says CEO and President Scott Melville during his address on 2017 priorities during the CHPA Annual Executive Conference in Amelia Island, Fla. March 21.

Technology Gap Separates OTC Drug Firms From Self-Care Sales Growth

OTC drug firms should offer more digital tools that guide consumers in product purchases, says a health care marketing executive. The American Pharmacists Association suggests firms also strengthen outreach with pharmacists.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel